NCT07135986View on ClinicalTrials.gov

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,504

Participants

Timeline

Start Date

September 26, 2025

Primary Completion Date

January 28, 2026

Study Completion Date

June 29, 2026

Conditions
Meningococcal InfectionHealthy Volunteers
Interventions
BIOLOGICAL

MenACYW conjugate vaccine

Pharmaceutical form:Liquid solution-Route of administration:Intramuscular (IM) injection

BIOLOGICAL

MenAC conjugate vaccine

Pharmaceutical form:Suspension-Route of administration:IM injection

BIOLOGICAL

MenAC conjugate vaccine

Pharmaceutical form:Lyophilized powder-Route of administration:IM injection

Trial Locations (1)

530028

RECRUITING

Investigational Site Number : 1561000, Nanning

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT07135986 - Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China | Biotech Hunter | Biotech Hunter